BMS-986446 is an investigational anti-MTBR-tau humanized monoclonal antibody being developed for early Alzheimer's disease as a potential disease-modifying therapy. The program is in Phase 2 development and has FDA Fast Track designation. It is not yet approved for clinical marketing.
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06268886 |
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06084598 |
A Study to Evaluate the Safety, Tolerability and Drug Levels of BMS-986446 in Healthy Participants and Healthy Participants of Japanese Ethnicity |
COMPLETED | PHASE1 |
